Comparative Study of Antibacterial Effect on Silver Dressing of Negative Pressure Wound

NCT ID: NCT02274207

Last Updated: 2015-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

74 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-31

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test therapeutic benefits of silver dressing compared with non-silver dressing in NPWT(Negative pressure wound therapy). Silver dressing may antibacterial effect on infected diabetes mellitus foot.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Investigator will recruit sixty patients. Participant will be randomly assigned to one of two groups. One is using silver dressing group in NPWT, another is using non-silver dressing group in NPWT. Participant will visit in screening day, NPWT apply day and F/u day for 4 months. Investigators will conduct to check the wound base, Lab, wound culture.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

silver dressing

Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea

Group Type EXPERIMENTAL

NPWT application

Intervention Type DEVICE

NPWT mode is cyclic mode : -125\~-50 mmHg

non-silver dressing

Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea

Group Type ACTIVE_COMPARATOR

NPWT application

Intervention Type DEVICE

NPWT mode is cyclic mode : -125\~-50 mmHg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NPWT application

NPWT mode is cyclic mode : -125\~-50 mmHg

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient above 20 years and has type I, II of diabetes mellitus foot ulcer
* Infected ulcer has one of below.

1. clinically infection symptom in ulcer area : warmth, erythema, tenderness/swelling

* induration, purulent discharge etc.
2. Confirmed case of bacteria in wound culture.
3. Conformed case of abnormal range of erythrocyte sedimentation rate (ESR)/C-reactive protein(CRP) level in lab.
* Has to be applied NPWT because suture is impossible in ulcer area.
* The patient voluntary agreed to this protocol.
* In the opinion of investigator, It is suitable to participate in this study.

Exclusion Criteria

* Infection in bone so patient need amputation
* Female with childbearing, lactating or not agree to prevent pregnancy.
* Has Sepsis, Osteomyelitis
* Has Connective tissue disease of disturbance of healing of wound Ex) Rheumarthritis,systemic lupus erythematosus(SEL), myalgia.
* The patient to diagnosis of Sickle sell disease or Charcot's joint.
* The patient stability treated chronic wasting disease.
* Malignant tumor or history of malignant disease. (Not diagnosis of complete recovery.)
* The patient treated chemotherapy, radiation therapy, immune-suppressants therapy,adrenocortical hormones therapy.
* Although necrosis tissue is removed, the target ulcer did not heal because of gangrenous, necrosis tissue or purulent pyorrhea.
* Has ulcer with cardiac arrhythmia thrombus, venous insufficiency, diabetic necrobiosis lipoidic.
* In case of using prohibited concomitant medications during study.

a. Oral system steroid b. Immune-suppressive drug c. Unfractionated heparin infusion d. improper drugs in the opinion of investigator.
* Hypersensitivity with applicators. (NPWT, Silver)
* The patient participated in other clinical trials within 30 days
* In the opinion of investigator, the patient is not suitable to participate in this study.
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Severance Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Woojin Choi

Orthopedics

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

WooJin Choi, MD

Role: PRINCIPAL_INVESTIGATOR

Korea: Severance hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Severance Hospital

Seoul, Seoul, South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Woo Jin Choi, MD

Role: CONTACT

82)2-2228-2195

Heiji Han, bachelor

Role: CONTACT

82)10-5086-7812

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Woojin Choi, MD

Role: primary

82)2-2228-2195

Heiji Han, bechelor

Role: backup

82)2-2228-2195

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CGBIOW1404

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

SS-14-NPWT

Identifier Type: -

Identifier Source: org_study_id